QRG Capital Management Inc. Purchases 4,144 Shares of BioNTech SE (NASDAQ:BNTX)

QRG Capital Management Inc. boosted its position in BioNTech SE (NASDAQ:BNTX) by 32.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,731 shares of the company’s stock after purchasing an additional 4,144 shares during the quarter. QRG Capital Management Inc.’s holdings in BioNTech were worth $1,543,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of BNTX. Harding Loevner LP purchased a new stake in shares of BioNTech in the fourth quarter worth $410,984,000. Primecap Management Co. CA increased its stake in BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of BioNTech by 43.1% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after acquiring an additional 127,951 shares in the last quarter. abrdn plc bought a new stake in shares of BioNTech during the 4th quarter valued at about $10,961,000. Finally, Baillie Gifford & Co. grew its holdings in shares of BioNTech by 1.0% during the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after purchasing an additional 86,343 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BNTX shares. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. BMO Capital Markets dropped their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. Evercore ISI began coverage on BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. UBS Group lowered their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $111.70.

BioNTech Trading Up 0.0 %

Shares of NASDAQ BNTX traded up $0.04 during midday trading on Wednesday, reaching $86.86. The company had a trading volume of 75,360 shares, compared to its average volume of 703,216. The stock has a market cap of $20.65 billion, a PE ratio of 173.64 and a beta of 0.23. BioNTech SE has a one year low of $78.02 and a one year high of $125.83. The firm’s fifty day moving average price is $90.34 and its 200-day moving average price is $92.71. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. On average, equities research analysts anticipate that BioNTech SE will post -2 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.